Indomethacin protects rats from neuronal damage induced by traumatic brain injury and suppresses hippocampal IL-1β release through the inhibition of Nogo-A expression

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Chao, Po Kuan ^a   Lu, Kwok Tung ^a   Jhu, Ji Yi ^b   Wo, Yu Yuan P ^b   Huang, Tai Chun ^a   Ro, Long Sun ^c   Yang, Yi Ling ^b  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

IL 1 ; Inflammation; Nogo A; Traumatic brain injury

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EOSIN; HEMATOXYLIN; INDOMETACIN; INTERLEUKIN 1BETA; PROTEIN NOGO A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN EDEMA; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MALE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRAUMATIC BRAIN INJURY; UPREGULATION; WESTERN BLOTTING;

EID: 84861855327     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-121     Document Type: Article

References (49)

1. Max W, Rice DP, MacKenzie EJ. The lifetime cost of injury. Inquiry 1990, 27:332-343.
2. Kraus JF, McArthur DL. Epidemiology of violent injury in the workplace. Occup Med 1996, 11:201-217.
3. Chua KS, Ng YS, Yap SG, Bok CW. A brief review of traumatic brain injury rehabilitation. Ann Acad Med Singapore 2007, 36:31-42.
4. Marshall LF. Head injury: recent past, present, and future. Neurosurgery 2000, 47:546-561.
5. Bramlett HM, Dietrich WD. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res 2007, 161:125-141.
6. Correale J, Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004, 251:1304-1316. 10.1007/s00415-004-0649-z, 15592725.
7. Lu KT, Wang YW, Yang JT, Yang YL, Chen HI. Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J Neurotrauma 2005, 22:885-895. 10.1089/neu.2005.22.885, 16083355.
8. Morganti-Kossmann MC, Rancan M, Otto VI, Stahel PF, Kossmann T. Role of cerebral inflammation after traumatic brain injury: a revisited concept. Shock 2001, 16:165-177. 10.1097/00024382-200116030-00001, 11531017.
9. Rothwell NJ. Annual review prize lecture: cytokines-killers in the brain?. J Physiol 1999, 514:3-17. 10.1111/j.1469-7793.1999.003af.x, 2269053, 9831712.
10. Tehranian R, Andell-Jonsson S, Beni SM, Yatsiv I, Shohami E, Bartfai T, Lundkvist J, Iverfeldt K. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002, 19:939-951. 10.1089/089771502320317096, 12225654.
11. Toulmond S, Rothwell NJ. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res 1995, 671:261-266. 10.1016/0006-8993(94)01343-G, 7743213.
12. Chen T, Liu W, Chao X, Zhang L, Qu Y, Huo J, Fei Z. Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice. Brain Res Bull 2011, 84:163-168. 10.1016/j.brainresbull.2010.11.015, 21134421.
13. Lynch JR, Wang H, Mace B, Leinenweber S, Warner DS, Bennett MP, Vitek S, McKenna S, Laskowitz DT. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005, 192:109-116. 10.1016/j.expneurol.2004.11.014, 15698624.
14. Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001, 409:341-346. 10.1038/35053072, 11201742.
15. Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, Giger RJ. The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J Neurosci 2005, 25:808-822. 10.1523/JNEUROSCI.4464-04.2005, 15673660.
16. Huber AB, Weinmann O, Brösamle C, Oertle T, Schwab ME. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci 2002, 22:3553-3567.
17. Hunt D, Coffin RS, Prinjha RK, Campbell G, Anderson PN. Nogo-A expression in the intact and injured nervous system. Mol Cell Neurosci 2003, 4:1083-1102.
18. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, Schwab ME. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439. 10.1038/35000219, 10667796.
19. GrandPré T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403:439-444. 10.1038/35000226, 10667797.
20. GrandPré T, Li S, Strittmatter SM. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002, 417:547-551. 10.1038/417547a, 12037567.
21. Papadopoulos CM, Tsai SY, Cheatwood JL, Bollnow MR, Kolb BE, Schwab ME, Kartje GL. Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb Cortex 2006, 16:529-536.
22. Seymour AB, Andrews EM, Tsai SY, Markus TM, Bollnow MR, Brenneman MM, O'Brien TE, Castro AJ, Schwab ME, Kartje GL. Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats. J Cereb Blood Flow Metab 2005, 25:1366-1375. 10.1038/sj.jcbfm.9600134, 15889044.
23. Fry EJ, Ho C, David S. A role for Nogo receptor in macrophage clearance from injured peripheral nerve. Neuron 2007, 53:649-662. 10.1016/j.neuron.2007.02.009, 17329206.
24. David S, Fry EJ, López-Vales R. Novel roles for Nogo receptor in inflammation and disease. Trends Neurosci 2008, 31:221-226. 10.1016/j.tins.2008.02.002, 18394723.
25. Lu KT, Cheng NC, Wu CY, Yang YL. NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade. Crit Care Med 2008, 36:917-922. 10.1097/CCM.0B013E31816590C4, 18431281.
26. Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 1994, 80:291-300. 10.3171/jns.1994.80.2.0291, 8283269.
27. Yuan RD, Ye J, Peng XJ, Liu SZ. Effects of antisense oligonucleotide on Nogo A mRNA expression in injured optic nerves. Int J Ophthalmol (Guoji Yanke Zazhi 2007, 7:354-356.
28. Chen H, Luo J, Kintner DB, Shull GE, Sun D. Na-dependent chloride transporter (NKCC1) null mice exhibit less gray and white matter damage after focal cerebral ischemia. J Cereb Blood Flow Metab 2005, 25:54-66. 10.1038/sj.jcbfm.9600006, 15678112.
29. Wang H, Yao Y, Jiang X, Chen D, Xiong Y, Mu D. Expression of Nogo-A and NGR in the developing rat brain after hypoxia-ischemia. Brain Res 2006, 1114:212-220. 10.1016/j.brainres.2006.07.056, 16928363.
30. Z'Graggen WJ, Fouad K, Raineteau O, Metz GA, Schwab ME, Kartje GL. Compensatory sprouting and impulse rerouting after unilateral pyramidal tract lesion in neonatal rats. J Neurosci 2000, 20:6561-6569.
31. Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL. Nogo-A expression after focal ischemic stroke in the adult rat. Stroke 2008, 39:2091-2098. 10.1161/STROKEAHA.107.507426, 18467652.
32. Lee JK, Kim JE, Sivula M, Strittmatter SM. Nogo receptor antagonism promotes stroke receovery by enhancing axonal plasticity. J Neurosci 2004, 24:6209-6217. 10.1523/JNEUROSCI.1643-04.2004, 15240813.
33. Markus TM, Tsai SY, Bollnow MR, Farrer RG, O'Brien TE, Kindler-Baumann DR, Rausch M, Rudin M, Wiessner C, Mir AK, Schwab ME, Kartje GL. Recovery and brain reorganization after stroke in adult and aged rats. Ann Neurol 2005, 58:950-953. 10.1002/ana.20676, 16315284.
34. Marklund N, Bareyre FM, Royo NC, Thompson HJ, Mir AK, Grady MS, Schwab ME, McIntosh TK. Cognitive outcome following brain injury and treatment with an inhibitor of Nogo-A in association with an attenuated downregulation of hippocampal growth-associated protein-43 expression. J Neurosurg 2007, 107:844-853. 10.3171/JNS-07/10/0844, 2366808, 17937233.
35. Marklund N, Morales D, Clausen F, Hånell A, Kiwanuka O, Pitkänen A, Gimbel DA, Philipson O, Lannfelt L, Hillered L, Strittmatter SM, McIntosh TK. Functional outcome is impaired following traumatic brain injury in aging Nogo-A/B-deficient mice. Neuroscience 2009, 163:540-551. 10.1016/j.neuroscience.2009.06.042, 2756649, 19555742.
36. Hånell A, Clausen F, Björk M, Jansson K, Philipson O, Nilsson LN, Hillered L, Weinreb PH, Lee D, McIntosh TK, Gimbel DA, Strittmatter SM, Marklund N. Genetic deletion and pharmacological inhibition of Nogo-66 receptor impairs cognitive outcome after traumatic brain injury in mice. J Neurotrauma 2010, 27:1297-1309. 10.1089/neu.2009.1255, 2942864, 20486800.
37. Zagrebelsky M, Schweigreiter R, Bandtlow CE, Schwab ME, Korte M. Nogo-A stabilizes the architecture of hippocampal neurons. J Neurosci 2010, 30:13220-13234. 10.1523/JNEUROSCI.1044-10.2010, 20926648.
38. Tian DS, Liu JL, Xie MJ, Zhan Y, Qu WS, Yu ZY, Tang ZP, Pan DJ, Wang W. Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. J Neurochem 2009, 109:1658-1667. 10.1111/j.1471-4159.2009.06077.x, 19457130.
39. Koprivica V, Cho KS, Park JB, Yiu G, Atwal J, Gore B, Kim JA, Lin E, Tessier-Lavigne M, Chen DF, He Z. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 2005, 310:106-110. 10.1126/science.1115462, 16210539.
40. Slavik RS, Rhoney DH. Indomethacin: a review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients. Neurol Res 1999, 21:491-499.
41. Tofteng F, Larsen FS. The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004, 24:798-804.
42. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, Fiebich BL, Rosenberg GA. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 2007, 323:488-498. 10.1124/jpet.107.127035, 2270866, 17704356.
43. Butterworth RF. Neuroinflammation in acute liver failure: mechanisms and novel therapeutic targets. Neurochem Int 2011, 59:830-836. 10.1016/j.neuint.2011.07.014, 21864609.
44. Cernak I, Vink R, Zapple DN, Cruz MI, Ahmed F, Chang T, Fricke ST, Faden AI. The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in rats. Neurobiol Dis 2004, 17:29-43. 10.1016/j.nbd.2004.05.011, 15350963.
45. Kunz T, Marklund N, Hillered L, Oliw EH. Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J Neurotrauma 2002, 19:1051-1064. 10.1089/089771502760341965, 12482118.
46. Czigner A, Mihály A, Farkas O, Büki A, Krisztin-Péva B, Dobó E, Barzó P. Kinetics of the cellular immune response following closed head injury. Acta Neurochir (Wien) 2007, 149:281-289.
47. Mackrell PJ, Daly JM, Mestre JR, Stapleton PP, Howe LR, Subbaramaiah K, Dannenberg A. Elevated expression of cyclooxygenase-2 contributes to immune dysfunction in a murine model of trauma. J Surgery 2001, 130:826-833.
48. Yan Z, Stapleton PP, Freeman TA, Fuortes M, Daly JM. Enhanced expression of cyclooxygenase-2 and prostaglandin E2 in response toendotoxin after trauma is dependent on MAPK and NF-κB mechhanisms. Cell Immunol 2004, 232:116-126. 10.1016/j.cellimm.2005.03.001, 15890324.
49. Cernak I, Noble-Haeusslein LJ. Traumatic brain injury: an overview of pathobiology with emphasis on military populations. J Cereb Blood Flow Metab 2010, 30:255-266. 10.1038/jcbfm.2009.203, 2855235,2855235, 19809467.